ChitogenX Inc.

CHGX

CA1699161032

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 09:30:00 2024-04-23 am EDT			5-day change	1st Jan Change
0.065 ^CAD	0.00%		0.00%	0.00%

Feb. 28	Chitogenxinc. Announces Resignation of Philippe Deschamps from the Board of Directors	CI
Feb. 28	Chitogenx Inc. Announces CEO Changes	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about ChitogenX Inc.

Chitogenxinc. Announces Resignation of Philippe Deschamps from the Board of Directors	Feb. 27	CI
Chitogenx Inc. Announces CEO Changes	Feb. 27	CI
ChitogenX Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	Jan. 02	CI
Chitogenx Inc. Demonstrates ORTHO-R Efficacy and Osteoarthritidevelopment in Large Animal Study	Nov. 09	CI
ChitogenX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	23-09-29	CI
ChitogenX Inc. Receives Notice of Allowance for Key Patent in United States and Canada	23-09-28	CI
ChitogenX Concluded Enrolment For Its U.S. Multi-site Rotator Cuff Tear Repair Phase I/II Clinical Trial	23-09-26	MT
Chitogenx Concludes Enrolment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial	23-09-26	CI
ChitogenX Reports Q1 Results	23-06-30	MT
ChitogenX Inc. Reports Earnings Results for the First Quarter Ended April 30, 2023	23-06-29	CI
ChitogenX Inc. announced that it has received CAD 1.30825 million in funding	23-06-04	CI
ChitogenX Inc. Reports Earnings Results for the Full Year Ended January 31, 2023	23-05-31	CI
ChitogenX Inc. Auditor Raises 'Going Concern' Doubt	23-05-30	CI
ChitogenX Completes Non-Brokered Private Placement	23-05-05	MT
ChitogenX Inc. announced that it has received CAD 3.856348 million in funding	23-05-04	CI
ChitogenX Inc. announced that it expects to receive CAD 2.5 million in funding	23-04-03	CI
ChitogenX Inc. announced that it has received CAD 6.1 million in funding	23-02-27	CI
ChitogenX Inc. Demonstrates Ortho-R Residency Properties in Meniscus Study	23-02-14	CI
ChitogenX Inc. announced that it expects to receive CAD 6.1 million in funding	23-02-08	CI
ChitogenX Reports Loss for Fiscal Q3, Higher Expenses	22-12-29	MT
ChitogenX Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	22-12-28	CI
ChitogenX Completes Phase I/II ORTHO-R Rotator Cuff Tear Repair Clinical Trial	22-11-09	MT
Chitogenx Successfully Completes Initial Portion of Its U.S. Phase I/Ii Rotator Cuff Repair Clinical Trial	22-11-09	CI
ChitogenX Inc. Up 3.5% as Signs MoU With California Medical Innovations Institute	22-10-19	MT
ChitogenX Inc. Signs Memorandum of Understanding with California Medical Innovations Institute	22-10-19	CI

ChitogenX Inc. is a Canada-based emerging orthopedic and sports medicine biologics company. The Company is engaged in the development of therapeutic soft tissue repair technologies to improve the success rate of orthopedic and sports medicine surgeries. The Companyâs proprietary biopolymer has been specifically designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, meniscus and cartilage. The biopolymer, autologous platelet-rich plasma (PRP) combination implant, can be directly placed into the site of injuries by surgeons during routine operative procedures without significantly extending the duration of surgeries and without further interventions. The Company assess its potential for therapeutic uses outside of the soft tissue repair market. The Company, through Ecole Polytechnique and two industrial partners, delineates the PRP components, the distinct impact of each component and their collective action towards tissue repair.

Sector

Biotechnology & Medical Research

Calendar

2024-05-28 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
CHITOGENX INC.	0.00%	3.95M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B